The Polypill - one pill for almost everything?
In 2003, British researchers first presented the idea of the polypill to the public. In addition to blood pressure-lowering drugs, it contains other agents such as cholesterol-lowering drugs (statins) and aspirin (ASA). The researchers suggested that the polypill should be taken preventively by everyone aged 55 and over. Regardless of whether or not individuals have personal cardiovascular risk factors, it is intended to reduce the risk of cardiovascular disease.
The participants were divided into two groups. One group received the polypill, the other did not. During the observation period, 301 of 3,417 in the control group, but only 202 of 3,421 participants in the polypill group, suffered a serious cardiovascular event. These events included hospital admission for acute coronary syndrome, a fatal heart attack, sudden death, heart failure, a coronary artery revascularization procedure, as well as non-fatal and fatal stroke. That means 99 more people were spared such an event in the group taking the polypill than in the comparison group.
The smaller US study also produced similar results. The 303 participants were low-income earners and mostly unable to afford health insurance. These people had to pay for medication and other costs themselves, as there is no statutory health insurance in the US. No participant had cardiovascular disease at the start of the study. Here too, the participants were divided into two groups. One group received a polypill, while the other did not. The study's observation period was twelve months. Medication adherence was over 80 percent, similar to the Iranian study.
The results were notable. In the treatment group the average systolic blood pressure fell by 9 mmHg, while in the comparison group without the polypill it fell by only 2 mmHg. LDL cholesterol also dropped much more in the polypill group: a 15 mg/dl reduction with the polypill versus only 4 mg/dl in the comparison group. So the mean LDL cholesterol fell by 11 mg/dl more in the treatment group.
Does that make the polypill a miracle drug for everyone?
As the two studies above show, a pill given preventively that contains several active ingredients can be beneficial in certain population groups. In both studies, participants came from groups that, for various reasons, have little access to medical care. Achieving an effect in these groups is therefore much more likely than in groups with good medical care. In the study populations, the chance of reaching people with undiagnosed high blood pressure or elevated blood lipids was relatively high. For healthy people in the group, taking a blood pressure drug isn't that problematic because it only lowers blood pressure a little. This „shotgun therapy“ is viewed more critically with regard to the statins and aspirin also included in the polypill, as aspirin can increase the risk of bleeding. This, like the unnecessary use of statins, is seen as a risk that cannot be properly calculated.
An earlier review by English and American physicians showed that the polypill was not more effective than the corresponding individual drugs. It also contains fixed doses of the individual active ingredients and therefore cannot be adjusted as flexibly as when the active ingredients are administered separately. This applies to targeted prescribing for patients with cardiovascular risk factors. Healthy people over 55 benefit more from a healthy lifestyle than from the idea mentioned at the outset of giving the polypill preventively to everyone from that age.
Rethinking the polypill
In 2022 the concept of the previously little-noticed polypill was reconsidered. One study looked at a polypill made up of three drugs that nearly every patient receives as long-term medication after having a heart attack. These are: aspirin as a platelet inhibitor, an ACE inhibitor (ramipril), and the statin atorvastatin, each available in several strengths, resulting in six different strength combinations for the polypill.
The reduced pill burden - that is, the smaller number of tablets patients have to take - led to significantly better adherence among patients in the observational group. After six months, 70.6% were taking their medication regularly; by contrast, only 62.7% were still doing so in the comparison group, which received the three components as separate medications instead of a polypill. After two years, medication use improved slightly in both groups: 74.1% of patients in the polypill group and 63.2% in the control group regularly took their prescribed medications.
After about three years of follow-up, the improved adherence also had an effect on the occurrence of heart attacks, strokes, urgent procedures to clear narrowed vessels, and deaths from cardiovascular disease. In the observation group, 9.5% of participants experienced such an event, while in the control group 12.7% were affected. The difference was especially clear for deaths: 5.8% of participants in the comparison group died during the follow-up period, while only 3.9% of those receiving the polypill did not reach the end of the follow-up period.
Because the polypill did not increase side effects or pose any safety risks, it could be a viable option for secondary prevention after a heart attack.
Sources:
- https://www.nejm.org/doi/full/10.1056/NEJMoa1815359?query=featured_home
- https://www.aerztezeitung.de/Medizin/Mit-Polypille-weniger-Herzinfarkte-und-Schlaganfaelle-314849.html
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31791-X/fulltext
- https://www.assmann-stiftung.de/polypille-bewaehrt-sich-in-der-primaerpraevention-von-herzinfarkt-und-schlaganfall-319/
- https://www.test.de/Polypillen-Praktisch-aber-nicht-wirksamer-5196168-0/
- https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009868.pub3/abstract
- https://www.pharmazeutische-zeitung.de/polypille-ueberzeugt-in-langzeitstudie/
- https://www.aerzteblatt.de/nachrichten/136964/Sekundaerprophylaxe-Polypille-schuetzt-nach-Herzinfarkt-besser
- https://www.nejm.org/doi/pdf/10.1056/NEJMoa2208275
This article is from Tensana – the leading app since 2011, helping hundreds of thousands of people monitor their blood pressure every day.
Our content is based on carefully researched, evidence-based data and is continuously updated (as of 02/2026).
Author Sabine Croci is a qualified medical assistant with many years of experience in internal medicine and cardiology practices as well as outpatient care, and has headed the specialist editorial team at Tensana since 2015. Thanks to her extensive additional qualifications as an emergency medical technician, first responder, and in various areas of therapy and emergency care, she provides well-founded, practical, and reliably verified information.
Author Sabine Croci is a qualified medical assistant with many years of experience in internal medicine and cardiology practices as well as outpatient care, and has headed the specialist editorial team at Tensana since 2015. Thanks to her extensive additional qualifications as an emergency medical technician, first responder, and in various areas of therapy and emergency care, she provides well-founded, practical, and reliably verified information.
